GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease

ACS Nano

Volumn 9, Issue 11, 2015, Pages 10801-10816

  Huang, Meng ^a   Hu, Meng ^a   Song, Qingxiang ^a   Song, Huahua ^a   Huang, Jialin ^a   Gu, Xiao ^a   Wang, Xiaolin ^a   Chen, Jun ^b   Kang, Ting ^b   Feng, Xingye ^b   Jiang, Di ^b   Zheng, Gang ^c   Chen, Hongzhuan ^a   Gao, Xiaoling ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; amyloid ; combination therapy; GM1 ganglioside; intranasal administration; nanoplatform; reconstituted high density lipoprotein

Indexed keywords

BINDING ENERGY; BIOMIMETICS; CYTOTOXICITY; GLYCOPROTEINS; LIPOPROTEINS; NANOSTRUCTURES; NEURODEGENERATIVE DISEASES; NEURONS;

ALZHEIMER'S DISEASE; COMBINATION THERAPY; GM1 GANGLIOSIDE; HIGH DENSITY LIPOPROTEIN; INTRANASAL; NANOPLATFORM;

DISEASE CONTROL;

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; GANGLIOSIDE GM1; GLUTAMIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; NEUROPROTECTIVE AGENT; PEPTIDE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL; BRAIN; CHEMISTRY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENDOCYTOSIS; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRANASAL DRUG ADMINISTRATION; MEMORY DISORDERS; METABOLISM; MICROGLIA; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; NEUROPROTECTION; PARTICLE SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT; STATIC ELECTRICITY; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; BRAIN; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; G(M1) GANGLIOSIDE; GLUTAMATES; LIPOPROTEINS, HDL; MEMORY DISORDERS; MICE, INBRED ICR; MICROGLIA; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; PARTICLE SIZE; PEPTIDE FRAGMENTS; PEPTIDES; RATS, SPRAGUE-DAWLEY; STATIC ELECTRICITY; TISSUE DISTRIBUTION;

EID: 84948462692     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b03124     Document Type: Article

References (80)

1. Gilbert, B. J. The Role of Amyloid Beta in the Pathogenesis of Alzheimer's Disease J. Clin. Pathol. 2013, 66, 362-366 10.1136/jclinpath-2013-201515
2. Wildsmith, K. R.; Holley, M.; Savage, J. C.; Skerrett, R.; Landreth, G. E. Evidence for Impaired Amyloid Beta Clearance in Alzheimer's Disease Alzheimer's Res. Ther. 2013, 5, 33 10.1186/alzrt187
3. Mawuenyega, K. G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J. C.; Yarasheski, K. E.; Bateman, R. J. Decreased Clearance of CNS Beta-Amyloid in Alzheimer's Disease Science 2010, 330, 1774 10.1126/science.1197623
4. Castellano, J. M.; Kim, J.; Stewart, F. R.; Jiang, H.; DeMattos, R. B.; Patterson, B. W.; Fagan, A. M.; Morris, J. C.; Mawuenyega, K. G.; Cruchaga, C. et al. Human ApoE Isoforms Differentially Regulate Brain Amyloid-Beta Peptide Clearance Sci. Transl. Med. 2011, 3, 57r-89r 10.1126/scitranslmed.3002156
5. Wisniewski, T.; Goni, F. Immunotherapeutic Approaches for Alzheimer's Disease Neuron 2015, 85, 1162-1176 10.1016/j.neuron.2014.12.064
6. Panza, F.; Frisardi, V.; Imbimbo, B. P.; D'Onofrio, G.; Pietrarossa, G.; Seripa, D.; Pilotto, A.; Solfrizzi, V. Bapineuzumab: Anti-Beta-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Immunotherapy 2010, 2, 767-782 10.2217/imt.10.80
7. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R. W.; Bullock, R.; Love, S.; Neal, J. W. et al. Long-Term Effects of Abeta42 Immunisation in Alzheimer's Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial Lancet 2008, 372, 216-223 10.1016/S0140-6736(08)61075-2
8. Liu, Y. H.; Giunta, B.; Zhou, H. D.; Tan, J.; Wang, Y. J. Immunotherapy for Alzheimer Disease: The Challenge of Adverse Effects Nat. Rev. Neurol. 2012, 8, 465-469 10.1038/nrneurol.2012.118
9. Hyman, B. T. Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease Arch. Neurol. 2011, 68, 1062-1064 10.1001/archneurol.2011.70
10. Prada, C. M.; Garcia-Alloza, M.; Betensky, R. A.; Zhang-Nunes, S. X.; Greenberg, S. M.; Bacskai, B. J.; Frosch, M. P. Antibody-Mediated Clearance of Amyloid-Beta Peptide From Cerebral Amyloid Angiopathy Revealed by Quantitative in vivo Imaging J. Neurosci. 2007, 27, 1973-1980 10.1523/JNEUROSCI.5426-06.2007
11. Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L.; Goebel, W. D.; James, M. J. et al. ApoE-Directed Therapeutics Rapidly Clear Beta-Amyloid and Reverse Deficits in AD Mouse Models Science 2012, 335, 1503-1506 10.1126/science.1217697
12. Mansoori, G. A.; Nazem, A. Nanotechnology Building Blocks for Intervention with Alzheimer's Disease Pathology: Implications in Disease Modifying Strategies J. Bioanal. Biomed. 2014, 6, 9-14 10.4172/1948-593X.1000101
13. Meng, H.; Mai, W. X.; Zhang, H.; Xue, M.; Xia, T.; Lin, S.; Wang, X.; Zhao, Y.; Ji, Z.; Zink, J. I. et al. Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles to Overcome Drug Resistance in Breast Cancer in vitro and in vivo ACS Nano 2013, 7, 994-1005 10.1021/nn3044066
14. Zhang, B.; Sun, X.; Mei, H.; Wang, Y.; Liao, Z.; Chen, J.; Zhang, Q.; Hu, Y.; Pang, Z.; Jiang, X. LDLR-Mediated Peptide-22-Conjugated Nanoparticles for Dual-Targeting Therapy of Brain Glioma Biomaterials 2013, 34, 9171-9182 10.1016/j.biomaterials.2013.08.039
15. Xu, L.; Liu, Y.; Chen, Z.; Li, W.; Liu, Y.; Wang, L.; Ma, L.; Shao, Y.; Zhao, Y.; Chen, C. Morphologically Virus-Like Fullerenol Nanoparticles Act as the Dual-Functional Nanoadjuvant for HIV-1 Vaccine Adv. Mater. 2013, 25, 5928-5936 10.1002/adma.201300583
16. Song, Q.; Huang, M.; Yao, L.; Wang, X.; Gu, X.; Chen, J.; Chen, J.; Huang, J.; Hu, Q.; Kang, T. et al. Lipoprotein-Based Nanoparticles Rescue the Memory Loss of Mice with Alzheimer's Disease by Accelerating the Clearance of Amyloid-Beta ACS Nano 2014, 8, 2345-2359 10.1021/nn4058215
17. Bricarello, D. A.; Smilowitz, J. T.; Zivkovic, A. M.; German, J. B.; Parikh, A. N. Reconstituted Lipoprotein: A Versatile Class of Biologically-Inspired Nanostructures ACS Nano 2011, 5, 42-57 10.1021/nn103098m
18. Bohrmann, B.; Baumann, K.; Benz, J.; Gerber, F.; Huber, W.; Knoflach, F.; Messer, J.; Oroszlan, K.; Rauchenberger, R.; Richter, W. F. et al. Gantenerumab: A Novel Human Anti-Abeta Antibody Demonstrates Sustained Cerebral Amyloid-Beta Binding and Elicits Cell-Mediated Removal of Human Amyloid-Beta J. Alzheimers Dis. 2012, 28, 49-69
19. Salloway, S.; Sperling, R.; Gilman, S.; Fox, N. C.; Blennow, K.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Doody, R.; van Dyck, C. H. et al. A Phase 2 Multiple Ascending Dose Trial of Bapineuzumab in Mild to Moderate Alzheimer Disease Neurology 2009, 73, 2061-2070 10.1212/WNL.0b013e3181c67808
20. Tokuda, T.; Calero, M.; Matsubara, E.; Vidal, R.; Kumar, A.; Permanne, B.; Zlokovic, B.; Smith, J. D.; Ladu, M. J.; Rostagno, A. et al. Lipidation of Apolipoprotein E Influences its Isoform-Specific Interaction with Alzheimer's Amyloid Beta Peptides Biochem. J. 2000, 348, 359-365 10.1042/0264-6021:3480359
21. Choo-Smith, L. P.; Garzon-Rodriguez, W.; Glabe, C. G.; Surewicz, W. K. Acceleration of Amyloid Fibril Formation by Specific Binding of Abeta-(1-40) Peptide to Ganglioside-Containing Membrane Vesicles J. Biol. Chem. 1997, 272, 22987-22990 10.1074/jbc.272.37.22987
22. Matsuoka, Y.; Saito, M.; LaFrancois, J.; Saito, M.; Gaynor, K.; Olm, V.; Wang, L.; Casey, E.; Lu, Y.; Shiratori, C. et al. Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to Beta-Amyloid J. Neurosci. 2003, 23, 29-33
23. Lin, Q.; Jin, C. S.; Huang, H.; Ding, L.; Zhang, Z.; Chen, J.; Zheng, G. Nanoparticle-Enabled, Image-Guided Treatment Planning of Target Specific RNAi Therapeutics in an Orthotopic Prostate Cancer Model Small 2014, 10, 3072-3082 10.1002/smll.201303842
24. Huang, C.; Jin, H.; Qian, Y.; Qi, S.; Luo, H.; Luo, Q.; Zhang, Z. Hybrid Melittin Cytolytic Peptide-Driven Ultrasmall Lipid Nanoparticles Block Melanoma Growth in vivo ACS Nano 2013, 7, 5791-5800 10.1021/nn400683s
25. Luo, H.; Lu, L.; Yang, F.; Wang, L.; Yang, X.; Luo, Q.; Zhang, Z. Nasopharyngeal Cancer-Specific Therapy Based On Fusion Peptide-Functionalized Lipid Nanoparticles ACS Nano 2014, 8, 4334-4347 10.1021/nn405989n
26. Sabnis, N.; Pratap, S.; Akopova, I.; Bowman, P. W.; Lacko, A. G. Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma Front. Pediatr. 2013, 1, 6 10.3389/fped.2013.00006
27. Wang, J.; Jia, J.; Liu, J.; He, H.; Zhang, W.; Li, Z. Tumor Targeting Effects of a Novel Modified Paclitaxel-Loaded Discoidal Mimic High Density Lipoproteins Drug Delivery 2013, 20, 356-363 10.3109/10717544.2013.834418
28. Freiherr, J.; Hallschmid, M.; Frey, W. N.; Brunner, Y. F.; Chapman, C. D.; Holscher, C.; Craft, S.; De Felice, F. G.; Benedict, C. Intranasal Insulin as a Treatment for Alzheimer's Disease: A Review of Basic Research and Clinical Evidence CNS Drugs 2013, 27, 505-514 10.1007/s40263-013-0076-8
29. Kostomoiri, M.; Zikos, C.; Benaki, D.; Triantis, C.; Sagnou, M.; Paravatou-Petsotas, M.; Papadaki, A.; Boleti, H.; Papadopoulos, M.; Pirmettis, I. et al. New Labeled Derivatives of the Neuroprotective Peptide Colivelin: Synthesis, Characterization, and First in vitro and in vivo Applications Arch. Biochem. Biophys. 2015, 567, 83-93 10.1016/j.abb.2014.12.027
30. Bassan, M.; Zamostiano, R.; Davidson, A.; Pinhasov, A.; Giladi, E.; Perl, O.; Bassan, H.; Blat, C.; Gibney, G.; Glazner, G. et al. Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide J. Neurochem. 1999, 72, 1283-1293 10.1046/j.1471-4159.1999.0721283.x
31. Gozes, I.; Divinski, I.; Piltzer, I. NAP and D-SAL: Neuroprotection Against the Beta Amyloid Peptide (1-42) BMC Neurosci. 2008, 9, S3 10.1186/1471-2202-9-S3-S3
32. Yang, C.; Liu, H. Z.; Lu, W. D.; Fu, Z. X. PEG-Liposomal Oxaliplatin Potentialization of Antitumor Efficiency in a Nude Mouse Tumor-Xenograft Model of Colorectal Carcinoma Oncol. Rep. 2011, 25, 1621-1628 10.3892/or.2011.1238
33. Jones, M. K.; Zhang, L.; Catte, A.; Li, L.; Oda, M. N.; Ren, G.; Segrest, J. P. Assessment of the Validity of the Double Superhelix Model for Reconstituted High Density Lipoproteins: A Combined Computational-Experimental Approach J. Biol. Chem. 2010, 285, 41161-41171 10.1074/jbc.M110.187799
34. van Antwerpen, R.; Chen, G. C.; Pullinger, C. R.; Kane, J. P.; LaBelle, M.; Krauss, R. M.; Luna-Chavez, C.; Forte, T. M.; Gilkey, J. C. Cryo-Electron Microscopy of Low Density Lipoprotein and Reconstituted Discoidal High Density Lipoprotein: Imaging of the Apolipoprotein Moiety J. Lipid Res. 1997, 38, 659-669
35. Zhang, Z.; Cao, W.; Jin, H.; Lovell, J. F.; Yang, M.; Ding, L.; Chen, J.; Corbin, I.; Luo, Q.; Zheng, G. Biomimetic Nanocarrier for Direct Cytosolic Drug Delivery Angew. Chem., Int. Ed. 2009, 48, 9171-9175 10.1002/anie.200903112
36. Khumsupan, P.; Ramirez, R.; Khumsupan, D.; Narayanaswami, V. Apolipoprotein E LDL Receptor-Binding Domain-Containing High-Density Lipoprotein: A Nanovehicle to Transport Curcumin, an Antioxidant and Anti-Amyloid Bioflavonoid Biochim. Biophys. Acta, Biomembr. 2011, 1808, 352-359 10.1016/j.bbamem.2010.09.007
37. Ng, K. K.; Lovell, J. F.; Vedadi, A.; Hajian, T.; Zheng, G. Self-Assembled Porphyrin Nanodiscs with Structure-Dependent Activation for Phototherapy and Photodiagnostic Applications ACS Nano 2013, 7, 3484-3490 10.1021/nn400418y
38. Cormode, D. P.; Briley-Saebo, K. C.; Mulder, W. J.; Aguinaldo, J. G.; Barazza, A.; Ma, Y.; Fisher, E. A.; Fayad, Z. A. An ApoA-I Mimetic Peptide High-Density-Lipoprotein-Based MRI Contrast Agent for Atherosclerotic Plaque Composition Detection Small 2008, 4, 1437-1444 10.1002/smll.200701285
39. Narayanaswami, V.; Maiorano, J. N.; Dhanasekaran, P.; Ryan, R. O.; Phillips, M. C.; Lund-Katz, S.; Davidson, W. S. Helix Orientation of the Functional Domains in Apolipoprotein E in Discoidal High Density Lipoprotein Particles J. Biol. Chem. 2004, 279, 14273-14279 10.1074/jbc.M313318200
40. Fisher, C. A.; Narayanaswami, V.; Ryan, R. O. The Lipid-Associated Conformation of the Low Density Lipoprotein Receptor Binding Domain of Human Apolipoprotein E J. Biol. Chem. 2000, 275, 33601-33606 10.1074/jbc.M002643200
41. Anantharamaiah, G. M.; Jones, J. L.; Brouillette, C. G.; Schmidt, C. F.; Chung, B. H.; Hughes, T. A.; Bhown, A. S.; Segrest, J. P. Studies of Synthetic Peptide Analogs of the Amphipathic Helix. Structure of Complexes with Dimyristoyl Phosphatidylcholine J. Biol. Chem. 1985, 260, 10248-10255
42. Liu, Y. H.; Giunta, B.; Zhou, H. D.; Tan, J.; Wang, Y. J. Immunotherapy for Alzheimer Disease: The Challenge of Adverse Effects Nat. Rev. Neurol. 2012, 8, 465-469 10.1038/nrneurol.2012.118
43. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K. et al. Peripherally Administered Antibodies Against Amyloid Beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease Nat. Med. 2000, 6, 916-919 10.1038/78682
44. Jan, A.; Gokce, O.; Luthi-Carter, R.; Lashuel, H. A. The Ratio of Monomeric to Aggregated Forms of Abeta40 and Abeta42 is an Important Determinant of Amyloid-Beta Aggregation, Fibrillogenesis, and Toxicity J. Biol. Chem. 2008, 283, 28176-28189 10.1074/jbc.M803159200
45. Fowler, S. W.; Chiang, A. C.; Savjani, R. R.; Larson, M. E.; Sherman, M. A.; Schuler, D. R.; Cirrito, J. R.; Lesne, S. E.; Jankowsky, J. L. Genetic Modulation of Soluble Abeta Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease J. Neurosci. 2014, 34, 7871-7885 10.1523/JNEUROSCI.0572-14.2014
46. Dhuria, S. V.; Hanson, L. R.; Frey, W. N. Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations J. Pharm. Sci. 2009, 99, 1654-1673 10.1002/jps.21924
47. Goldsmith, M.; Abramovitz, L.; Peer, D. Precision Nanomedicine in Neurodegenerative Diseases ACS Nano 2014, 8, 1958-1965 10.1021/nn501292z
48. Innerarity, T. L.; Pitas, R. E.; Mahley, R. W. Lipoprotein-Receptor Interactions Methods Enzymol. 1986, 129, 542-565 10.1016/0076-6879(86)29091-6
49. Ueno, M.; Chiba, Y.; Matsumoto, K.; Nakagawa, T.; Miyanaka, H. Clearance of Beta-Amyloid in the Brain Curr. Med. Chem. 2014, 21, 4085-4090 10.2174/0929867321666141011194256
50. Sagare, A.; Deane, R.; Bell, R. D.; Johnson, B.; Hamm, K.; Pendu, R.; Marky, A.; Lenting, P. J.; Wu, Z.; Zarcone, T. et al. Clearance of Amyloid-Beta by Circulating Lipoprotein Receptors Nat. Med. 2007, 13, 1029-1031 10.1038/nm1635
51. Lee, C. Y.; Landreth, G. E. The Role of Microglia in Amyloid Clearance From the AD Brain J. Neural. Transm. 2010, 117, 949-960 10.1007/s00702-010-0433-4
52. McDonald, J. H.; Dunn, K. W. Statistical Tests for Measures of Colocalization in Biological Microscopy J. Microsc. 2013, 252, 295-302 10.1111/jmi.12093
53. Kawahara, K.; Suenobu, M.; Ohtsuka, H.; Kuniyasu, A.; Sugimoto, Y.; Nakagomi, M.; Fukasawa, H.; Shudo, K.; Nakayama, H. Cooperative Therapeutic Action of Retinoic Acid Receptor and Retinoid X Receptor Agonists in a Mouse Model of Alzheimer's Disease J. Alzheimers Dis. 2014, 42, 587-605
54. Castellano, J. M.; Deane, R.; Gottesdiener, A. J.; Verghese, P. B.; Stewart, F. R.; West, T.; Paoletti, A. C.; Kasper, T. R.; DeMattos, R. B.; Zlokovic, B. V. et al. Low-Density Lipoprotein Receptor Overexpression Enhances the Rate of Brain-to-Blood Abeta Clearance in a Mouse Model of Beta-Amyloidosis Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 15502-15507 10.1073/pnas.1206446109
55. Shibata, M.; Yamada, S.; Kumar, S. R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D. M.; Miller, C. A.; Strickland, D. K.; Ghiso, J. et al. Clearance of Alzheimer's Amyloid-ss(1-40) Peptide From Brain by LDL Receptor-Related Protein-1 at the Blood-Brain Barrier J. Clin. Invest. 2000, 106, 1489-1499 10.1172/JCI10498
56. Kakee, A.; Terasaki, T.; Sugiyama, Y. Brain Efflux Index as a Novel Method of Analyzing Efflux Transport at the Blood-Brain Barrier J. Pharmacol. Exp. Ther. 1996, 277, 1550-1559
57. Qosa, H.; Abuznait, A. H.; Hill, R. A.; Kaddoumi, A. Enhanced Brain Amyloid-Beta Clearance by Rifampicin and Caffeine as a Possible Protective Mechanism Against Alzheimer's Disease J. Alzheimers Dis. 2012, 31, 151-165
58. Szegedi, V.; Juhasz, G.; Budai, D.; Penke, B. Divergent Effects of Abeta1-42 on Ionotropic Glutamate Receptor-Mediated Responses in CA1 Neurons in Vivo Brain Res. 2005, 1062, 120-126 10.1016/j.brainres.2005.09.014
59. Yao, P. J.; Zhu, M.; Pyun, E. I.; Brooks, A. I.; Therianos, S.; Meyers, V. E.; Coleman, P. D. Defects in Expression of Genes Related to Synaptic Vesicle Trafficking in Frontal Cortex of Alzheimer's Disease Neurobiol. Dis. 2003, 12, 97-109 10.1016/S0969-9961(02)00009-8
60. Selkoe, D. J. Cell Biology of Protein Misfolding: The Examples of Alzheimer's and Parkinson's Diseases Nat. Cell Biol. 2004, 6, 1054-1061 10.1038/ncb1104-1054
61. Wang, Y.; Xia, Z.; Xu, J. R.; Wang, Y. X.; Hou, L. N.; Qiu, Y.; Chen, H. Z. Alpha-Mangostin, a Polyphenolic Xanthone Derivative From Mangosteen, Attenuates Beta-Amyloid Oligomers-Induced Neurotoxicity by Inhibiting Amyloid Aggregation Neuropharmacology 2012, 62, 871-881 10.1016/j.neuropharm.2011.09.016
62. Wu, H. Y.; Hudry, E.; Hashimoto, T.; Kuchibhotla, K.; Rozkalne, A.; Fan, Z.; Spires-Jones, T.; Xie, H.; Arbel-Ornath, M.; Grosskreutz, C. L. et al. Amyloid Beta Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation J. Neurosci. 2010, 30, 2636-2649 10.1523/JNEUROSCI.4456-09.2010
63. Meyer-Luehmann, M.; Spires-Jones, T. L.; Prada, C.; Garcia-Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D. M.; Bacskai, B. J.; Hyman, B. T. Rapid Appearance and Local Toxicity of Amyloid-Beta Plaques in a Mouse Model of Alzheimer's Disease Nature 2008, 451, 720-724 10.1038/nature06616
64. Mehta, A.; Prabhakar, M.; Kumar, P.; Deshmukh, R.; Sharma, P. L. Excitotoxicity: Bridge to Various Triggers in Neurodegenerative Disorders Eur. J. Pharmacol. 2013, 698, 6-18 10.1016/j.ejphar.2012.10.032
65. Coyle, J. T.; Puttfarcken, P. Oxidative Stress, Glutamate, and Neurodegenerative Disorders Science 1993, 262, 689-695 10.1126/science.7901908
66. Doble, A. The Role of Excitotoxicity in Neurodegenerative Disease: Implications for Therapy Pharmacol. Ther. 1999, 81, 163-221 10.1016/S0163-7258(98)00042-4
67. Talantova, M.; Sanz-Blasco, S.; Zhang, X.; Xia, P.; Akhtar, M. W.; Okamoto, S.; Dziewczapolski, G.; Nakamura, T.; Cao, G.; Pratt, A. E. et al. Abeta Induces Astrocytic Glutamate Release, Extrasynaptic NMDA Receptor Activation, and Synaptic Loss Proc. Natl. Acad. Sci. U. S. A. 2013, 110, E2518-E2527 10.1073/pnas.1306832110
68. Ferrari, G.; Greene, L. A. Promotion of Neuronal Survival by GM1 Ganglioside. Phenomenology and Mechanism of Action Ann. N. Y. Acad. Sci. 1998, 845, 263-273 10.1111/j.1749-6632.1998.tb09679.x
69. Marei, H. E.; Farag, A.; Althani, A.; Afifi, N.; Abd-Elmaksoud, A.; Lashen, S.; Rezk, S.; Pallini, R.; Casalbore, P.; Cenciarelli, C. Human Olfactory Bulb Neural Stem Cells Expressing hNGF Restore Cognitive Deficit in Alzheimer's Disease Rat Model J. Cell. Physiol. 2015, 230, 116-130 10.1002/jcp.24688
70. Nakamura, S.; Murayama, N.; Noshita, T.; Katsuragi, R.; Ohno, T. Cognitive Dysfunction Induced by Sequential Injection of Amyloid-Beta and Ibotenate into the Bilateral Hippocampus; Protection by Memantine and MK-801 Eur. J. Pharmacol. 2006, 548, 115-122 10.1016/j.ejphar.2006.07.049
71. Morimoto, K.; Yoshimi, K.; Tonohiro, T.; Yamada, N.; Oda, T.; Kaneko, I. Co-Injection of Beta-Amyloid with Ibotenic Acid Induces Synergistic Loss of Rat Hippocampal Neurons Neuroscience 1998, 84, 479-487 10.1016/S0306-4522(97)00507-1
72. Hruska, Z.; Dohanich, G. P. The Effects of Chronic Estradiol Treatment on Working Memory Deficits Induced by Combined Infusion of Beta-Amyloid (1-42) and Ibotenic Acid Horm. Behav. 2007, 52, 297-306 10.1016/j.yhbeh.2007.05.010
73. Dornan, W. A.; Kang, D. E.; McCampbell, A.; Kang, E. E. Bilateral Injections of Beta a(25-35) + IBO into the Hippocampus Disrupts Acquisition of Spatial Learning in the Rat NeuroReport 1993, 5, 165-168 10.1097/00001756-199311180-00018
74. Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Gu, G.; Song, Q.; Yao, L.; Hu, Q.; Tu, Y.; Pang, Z. et al. Lactoferrin-Modified PEG-co-PCL Nanoparticles for Enhanced Brain Delivery of NAP Peptide Following Intranasal Administration Biomaterials 2013, 34, 3870-3881 10.1016/j.biomaterials.2013.02.003
75. Li, J.; Zhang, C.; Li, J.; Fan, L.; Jiang, X.; Chen, J.; Pang, Z.; Zhang, Q. Brain Delivery of NAP with PEG-PLGA Nanoparticles Modified with Phage Display Peptides Pharm. Res. 2013, 30, 1813-1823 10.1007/s11095-013-1025-4
76. Yamagishi, M.; Nakamura, H.; Takahashi, S.; Nakano, Y.; Iwanaga, T. Olfactory Receptor Cells: Immunocytochemistry for Nervous System-Specific Proteins and Re-Evaluation of their Precursor Cells Arch. Histol. Cytol. 1989, 52 (Suppl) 375-381 10.1679/aohc.52.Suppl
77. Yamagishi, M.; Hasegawa, S.; Takahashi, S.; Nakano, Y.; Iwanaga, T. Immunohistochemical Analysis of the Olfactory Mucosa by Use of Antibodies to Brain Proteins and Cytokeratin Ann. Otol., Rhinol., Laryngol. 1989, 98, 384-388 10.1177/000348948909800514
78. Pellier, V.; Astic, L. Histochemical and Immunocytochemical Study of the Migration of Neurons from the Rat Olfactory Placode Cell Tissue Res. 1994, 275, 587-598 10.1007/BF00318827
79. Stine, W. J.; Dahlgren, K. N.; Krafft, G. A.; LaDu, M. J. In vitro Characterization of Conditions for Amyloid-Beta Peptide Oligomerization and Fibrillogenesis J. Biol. Chem. 2003, 278, 11612-11622 10.1074/jbc.M210207200
80. Kobayashi, Y.; Lederis, K.; Rivier, J.; Ko, D.; McMaster, D.; Poulin, P. Radioimmunoassays for Fish Tail Neuropeptides: II. Development of a Specific and Sensitive Assay for and the Occurrence of Immunoreactive Urotensin II in the Central Nervous System and Blood of Catostomus Commersoni J. Pharmacol. Methods 1986, 15, 321-333 10.1016/0160-5402(86)90011-2